Modis Therapeutics, Inc.

Zogenix Inc. has struck a deal to buy Modis Therapeutics Inc. for $250m upfront, giving it control of another late-phase rare disease drug to complement its lead product, Fintepla. The planned take

Here's your news in brief: The US FDA’s Center for Biologics Evaluation and Research approved its first novel therapy in 2019 with the clearance of Novo Nordisk AS ’s long-acting coagulation Factor V

Series A Round Brings $60m To 89bio Launched with small molecules licensed from Teva Pharmaceutical Industries Ltd. , 89bio concurrently raised $60m through its Series A round. Founding investors O